KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation

PURPOSE: There is an urgent need to develop effective therapies and treatment strategies to treat hypoxic tumors, which have a very poor prognosis and do not respond well to existing therapies. METHODS: A novel hypoxia-targeting agent, KEMTUB012-NI2, was synthesized by conjugating a 2-nitroimidazole...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazzari, Paolo, Spiga, Marco, Sani, Monica, Zanda, Matteo, Fleming, Ian N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448701/
https://www.ncbi.nlm.nih.gov/pubmed/28580362
http://dx.doi.org/10.2147/HP.S132832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448701/
https://www.ncbi.nlm.nih.gov/pubmed/28580362
http://dx.doi.org/10.2147/HP.S132832

Ejemplares similares